Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Maxxim Medical Management-Led Leveraged Buyout Valued At $800 Mil.

This article was originally published in The Gray Sheet

Executive Summary

The management of Maxxim Medical plans to take the specialty medical products company private with the help of Foster City, California-based investment firm Fox Paine & Company and Chase Manhattan.

You may also be interested in...



Maxxim Sale To Lightyear Resolves Bankruptcy; Management Likely To Stay

Investment firm Lightyear Capital's acquisition of Maxxim Medical will strengthen the procedure tray manufacturer's balance sheet and enable it to emerge from bankruptcy proceedings largely intact, the company asserts

Maxxim Sale To Lightyear Resolves Bankruptcy; Management Likely To Stay

Investment firm Lightyear Capital's acquisition of Maxxim Medical will strengthen the procedure tray manufacturer's balance sheet and enable it to emerge from bankruptcy proceedings largely intact, the company asserts

Maxxim Medical

Extends to Nov. 10 the expiration of its offer to purchase for cash any and all of the $100 mil. aggregate principal amount of its outstanding 10-1/2% senior subordinated notes due 2006. Holders of over $99.9 mil. of the notes had tendered their notes and delivered consents to amendments prior to the consent expiration date. Previously scheduled to expire on Oct. 29, the tender offer was launched in connection with Maxxim's previously announced proposal to merge with Fox Paine Medic Acquisition Corporation and recapitalize the company (1"The Gray Sheet" June 21, p. 19). The merger is expected to close in "mid-November," Maxxim says

Latest Headlines
See All
UsernamePublicRestriction

Register

MT011951

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel